Up to 50% of people do not adhere to their medication prescription direction and that 1 quarter of all medication related harm is associated with non-adherence (1)(2). This is translated into an annual NHS cost of £40 million in avoidable hospital re-admissions with additional costs on unused medications and further harm due to non-adherence (3). Furthermore, it can be difficult for health care practitioners to accurately identify those who are struggling to take their medication correctly.
The Identification of Medication Adherence Barriers Questionnaire intervention (IMAB-Qi) study is designed to support health care practitioners to work with patients attending medication reviews in primary to care to understand and address their barriers through evidence-based behaviour change therapies. Patients are sent the IMAB questionnaire with 10 agree/disagree statements which are then reviewed and discussed at their medication review before an appropriate course of action is agreed.
Health Innovation East was commissioned by the IMAB-Qi study team to provide implementation support during the Feasibility and Definitive Trials, as well co-development of study materials.
This support has included:
– Sharing of implementation expertise through focus groups and study workshops
– Supporting the development of trial and implementation activities
– Practice support of implementation of intervention materials
– Implementation support to implementing sites via kick-off meetings, weekly support calls and one-to-one support as needed
– Facilitation of communication between sites and study team during the implementation phase
– Spread of learning and best practice between implementation sites
The IMAB-Qi study was sponsored by the University of East Anglia
Do you have a great idea that could deliver meaningful change in the real world?
Get involved